Wealthcare Advisory Partners LLC lifted its position in GlaxoSmithKline plc (NYSE:GSK) by 1,982.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,520 shares of the pharmaceutical company’s stock after purchasing an additional 3,351 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in GlaxoSmithKline were worth $143,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of GSK. TD Asset Management Inc. raised its stake in shares of GlaxoSmithKline by 8.5% in the second quarter. TD Asset Management Inc. now owns 34,546 shares of the pharmaceutical company’s stock valued at $1,490,000 after purchasing an additional 2,698 shares in the last quarter. First Trust Advisors LP raised its stake in shares of GlaxoSmithKline by 3.2% in the second quarter. First Trust Advisors LP now owns 452,533 shares of the pharmaceutical company’s stock valued at $19,513,000 after purchasing an additional 14,240 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of GlaxoSmithKline by 11.2% in the second quarter. Advisors Asset Management Inc. now owns 157,995 shares of the pharmaceutical company’s stock valued at $6,813,000 after purchasing an additional 15,882 shares in the last quarter. Trillium Asset Management LLC raised its stake in shares of GlaxoSmithKline by 3.9% in the second quarter. Trillium Asset Management LLC now owns 72,562 shares of the pharmaceutical company’s stock valued at $3,129,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its stake in shares of GlaxoSmithKline by 16.1% in the second quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after purchasing an additional 457 shares in the last quarter. Institutional investors and hedge funds own 9.83% of the company’s stock.

In related news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.00% of the company’s stock.

GSK has been the subject of a number of recent research reports. BidaskClub upgraded GlaxoSmithKline from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Argus restated a “buy” rating and issued a $50.00 target price on shares of GlaxoSmithKline in a research note on Thursday, August 31st. Morgan Stanley lowered GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, September 14th. Finally, Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $39.37.

GlaxoSmithKline plc (NYSE GSK) opened at $35.58 on Thursday. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $44.53. The stock has a market capitalization of $87,356.00, a price-to-earnings ratio of 12.60, a price-to-earnings-growth ratio of 1.97 and a beta of 0.98.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.66%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is currently 163.12%.

ILLEGAL ACTIVITY NOTICE: “Wealthcare Advisory Partners LLC Boosts Stake in GlaxoSmithKline plc (GSK)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/14/wealthcare-advisory-partners-llc-boosts-stake-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related stocks with our FREE daily email newsletter.